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Abstract
Introduction: The purpose of this research is to provide recommendations for the management of glycemic
control in critically ill patients.
Methods: Twenty-one experts issued recommendations related to one of the five pre-defined categories (glucose
target, hypoglycemia, carbohydrate intake, monitoring of glycemia, algorithms and protocols), that were scored on
a scale to obtain a strong or weak agreement. The GRADE (Grade of Recommendation, Assessment, Development
and Evaluation) system was used, with a strong recommendation indicating a clear advantage for an intervention
and a weak recommendation indicating that the balance between desirable and undesirable effects of an
intervention is not clearly defined.
Results: A glucose target of less than 10 mmol/L is strongly suggested, using intravenous insulin following a
standard protocol, when spontaneous food intake is not possible. Definition of the severe hypoglycemia threshold
of 2.2 mmol/L is recommended, regardless of the clinical signs. A general, unique amount of glucose (enteral/
parenteral) to administer for any patient cannot be suggested. Glucose measurements should be performed on
arterial rather than venous or capillary samples, using central lab or blood gas analysers rather than point-of-care
glucose readers.
Conclusions: Thirty recommendations were obtained with a strong (21) and a weak (9) agreement. Among them,
only 15 were graded with a high level of quality of evidence, underlying the necessity to continue clinical studies
in order to improve the risk-to-benefit ratio of glucose control.
Introduction
Critically ill patients in intensive care units (ICUs)
develop insulin resistance that is responsible for so-
called “stress diabetes” [1-3]. For a long time this was
accepted insofar as stress diabetes was seen as an adap-
tive metabolic response. However, over the last 10 years,
there have been changes in clinical practice resulting
from a better knowledge of glucose toxicity and from
observations on the benefits of glucose control in clini-
cal trials [4]. Since the first trial in Leuven in 2001 [4], a
plethora of articles has been published on the subject
but these have triggered much controversy and confused
the clinician, with the result that clinical practice varies
widely. For this reason, the French Society of Anesthesia
and Intensive Care (Société Française d’Anesthésie-Réa-
nimation, SFAR) and the French-speaking Society for
Intensive Care (Société de Réanimation de Langue Fran-
çaise, SRLF) decided to develop expert panel consensus
recommendations. Published in 2008 [5], these were
updated in May 2009 after the publication of the NICE-
SUGAR trial [6]. This paper addresses the practical
aspects of glucose control in ICUs, the diagnosis and
risks of hypoglycemia, and how to monitor glucose
levels in ICU patients.
Materials and methods
A steering committee, comprising a chair, two SFAR
members, and two SRLF members, was set up in late
2007. This committee chose the topics to be addressed
and nominated the experts in charge of each specific
area. The choice of experts was validated by both socie-
ties; 21 French, Belgian and Swiss experts, as well as
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topic, accepted to participate in the development of the
recommendations. No member of the committee from
industry was present at any of the meetings.
The global process for elaborating recommendations
is summarised in Additional file 1, Table S1. The aim
of the first meeting was to explain the methodology of
the working group. Based on a MEDLINE search, each
subgroup of experts in charge of its topic had to pro-
duce a review including the analysis of the literature
and the arguments to propose recommendations. A
first version of recommendations was elaborated using
the GRADE method (Grade of Recommendation,
Assessment, Development and Evaluation) [7,8]. This
method takes into account the quality of evidence, the
balance between benefits versus harms, endpoint rele-
vance, and costs. As explained during the first meeting,
the quality of evidence of each recommendation was
systematically specified by the subgroups (Additional
file 1, Table S2). The global evidence quality was
therefore up- or downgraded by weighting for these
three extra factors. Each recommendation was thus
allocated a final level of evidence which determined its
wording: (i) we recommend (or we do not recommend)
for a strong recommendation, (ii) we strongly suggest
(or we strongly do not suggest) for a moderate recom-
mendation (iii) we suggest (or we do not suggest) for a
weak recommendation (Additional file 1, Table S2).
Each recommendation was then rated by all experts on
a scale from 1 to 9 (1 = disagreement, 9 = agreement).
A median score was calculated (after exclusion of the
h i g h e s to rl o w e s tr a t i n g ,i fn e c e s s a r y )t h a tc o u l df a l l
into one of three zones: (1 to 3) = disagreement; (4 to
6) = indecision; (7 to 9) = agreement. If the confidence
interval of the median was within the first or last zone,
the strength of the recommendation was considered to
be weak or strong, respectively (Figure 1). With this
methodology, we must distinguish the strength of
recommendation and the level of agreement (or dis-
agreement) obtained from the vote of the experts; for
example, it is possible to propose a weak recommenda-
tion with a strong agreement. Recommendations for
which agreement was not reached in a first round
were reworded in order to obtain a better consensus.
Up to three rounds were needed to reach an agree-
ment for all recommendations.
Excluding the specific problems of diabetic patients
and children, five items were analysed including: i) the
glycemic target in ICUs; ii) the diagnosis and conse-
quences of hypoglycemia in ICUs; iii) the rules for car-
bohydrate intake; iv) the glucose monitoring; and v) the
impact of algorithms and protocols. Recommendations
are summarized in Additional file 1, Table S3.
Results
Glucose target in ICUs
We strongly suggest avoidance of severe hyperglycemia
(> 10 mmol/L/180 mg/dL) in adult ICU patients. We
suggest keeping glucose levels under control although a
universally acceptable upper limit cannot be specified
(strong agreement).
We suggest avoidance of tight glucose control in an
emergency situation as this management seems to not
be reasonable and is potentially dangerous (strong
agreement).
We also strongly suggest avoidance of large variations
in glucose levels in ICUs (strong agreement).
We do not recommend using any drug other than
intravenous insulin for glucose control in ICUs (weak
agreement).
Hypoglycemia: diagnosis and harms
We suggest that in ICU patients, the glucose threshold
is probably <2.2 mmol/L (40 mg/dL) for severe hypogly-
cemia (strong agreement).
In ICU patients unable to express themselves, we
recommend that hypoglycemia be corrected even in the
absence of clinical signs (strong agreement).
We suggest that severe hypoglycemia is probably
associated with an increasedr i s ko fm o r t a l i t ya l t h o u g h
Figure 1 Process for determination of strong versus weak agreement. Each expert rated the recommendations on a scale from 1 to 9. A
median score ± confidence interval was then calculated based on all expert votes (if necessary, one isolated higher or lower value was
excluded). A median score between 1 and 3 indicated disagreement; a median score between 4 and 6 indicated indecision; a median score
between 7 and 9 agreement. If the confidence interval was within or without the previous defined zones, the strength of agreement (or
disagreement) was considered to be strong or weak, respectively.
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agreement).
Implementation of published strategies for tight glu-
cose control exposes patients to more frequent and
long-lasting severe hypoglycemia (strong agreement).
Long-lasting severe hypoglycemia can induce irreversi-
ble brain lesions. We suggest that neurological lesions
following hypoglycemia might be partly related to excess
glucose infusion (strong agreement).
In a strategy of tight glucose control, we recommend
closely monitoring glucose blood levels for the early
detection of severe hypoglycemia (strong agreement).
We recommend favoring arterial or venous blood
samples rather than capillary samples in ICU patients
with suspected hypoglycemia as capillary samples often
overestimate glucose (strong agreement).
Carbohydrate intake
We suggest reducing hyperglycemia by restricting intra-
venous glucose in critically ill patients (weak
agreement).
We suggest interrupting intravenous insulin infusion
by an electric syringe pump when the patient has
resumed food intake and to continue glucose monitor-
ing for at least three preprandial controls (strong
agreement).
We cannot suggest a general recommendation of max-
imal and minimal amounts of intravenous and/or ent-
eral carbohydrates be administered to critically ill
patients, regardless of the type, the severity of pathology
and of the delay from onset of disease (strong
agreement).
We suggest that glucose intake should not be prohib-
ited in critically ill patients provided that glycemia is
under control (weak agreement).
We suggest that compliance with the glucose target
might be improved by continuous adaptation of enteral
nutrition and insulin infusion rates (weak agreement).
Glucose monitoring
We recommend performing glucose measurements in
the laboratory; this remains the current gold standard
technique (strong agreement).
We recommend performing glucose measurements in
the following preferential order of sampling: arterial,
venous, capillary (strong agreement).
As total blood and plasma glucose measurements dif-
fer, we recommend knowing the specifications of the
device used (not all devices apply an automatic correc-
tion factor) (strong agreement).
Owing to endogenous and exogenous physicochemical
interference, we recommend being aware of the precise
specifications of the device and paper-strips that are
used (strong agreement).
Algorithms and protocols
We recommend defining and implementing a standard
protocol for glucose control in each medical team
(strong agreement).
Among available glucose control protocols, none may
be considered superior to any other (weak agreement).
We recommend including in a glucose control proto-
col, at the very least, recommendations on the use of
rapid action insulin as a continuous infusion by electric
syringe pump, as well as on correction and monitoring
procedures for episodes of hypoglycemia (strong
agreement).
We strongly suggest giving preference to a route of
administration providing a constant intravenous insulin
infusion rate (strong agreement).
We recommend no longer using static glucose control
protocols which determine insulin delivery rate on the
basis of the last glucose measurement (strong
agreement).
When using glucose control protocols, we strongly
suggest taking into account carbohydrate intake in the
determination of the insulin delivery rate (strong
agreement).
We suggest using a computer-assisted glucose control
protocol when there are more than two entries and out-
puts (weak agreement).
We strongly suggest that the efficacy of a glucose con-
trol protocol depends on all of the following criteria:
training time, glucose control performance, risk of hypo-
glycemia, mean error rate, nursing workload (weak
agreement).
We suggest assessing the efficacy of a glucose control
protocol by considering preferably the following vari-
ables: percent time in- and above-target, hyperglycemia
index, and variability (weak agreement).
We recommend taking into account the increase in
staff workload when implementing a tight glucose con-
trol protocol. We recommend allocating time to train
the staff before implementing the protocol (strong
agreement).
Discussion
Glucose target in ICUs
The deleterious impact of hyperglycemia in ICU
patients has long been overlooked. However, many
observational studies have confirmed that there is a link
between hyperglycemia and increased mortality in criti-
cally ill patients [9-13]. The decrease in mortality
reported in the 2001 Leuven trial after intensive insulin
therapy [4] led to a considerable change in clinical prac-
tice, with hyperglycemia in ICU patients becoming less
acceptable. This trial was a single-center prospective
randomized controlled trial (RCT) which compared
tight glucose control by intensive insulin therapy (IIT)
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ment (10 to 12.1 mmol/L) in surgical ICU patients. IIT
was associated with a decrease in ICU mortality from
8.0 to 4.6% and hospital mortality from 10.9 to 7.2%.
The beneficial effects of IIT were greater in patients
who spent more than five days in an ICU. A decrease
in ICU morbidity was also observed, including lower
incidence of systemic infections, acute renal insuffi-
ciency, anemia, polyneuropathy, duration of artificial
ventilation, and length of stay in the ICU.
However, since the 2001 Leuven trial, the results of
several RCTs have dampened the enthusiasm generated
by these early results [14-19]. Van den Berghe et al. per-
formed the same study in ICU medical patients, with
the same objectives and same method, and detected no
significant difference in mortality between groups [15].
Two other single-center studies found no decrease in
mortality and morbidity in medical and surgical ICU
patients receiving IIT [17,18]. Three multicenter RCTs
have been performed. The VISEP (Volume substitution
and Insulin therapy in severe sepsis) trial assessed the
impact of tight glucose control in patients with septic
shock or severe sepsis [16]. The 28-day and 90-day mor-
tality rates did not differ between the intensive insulin
therapy group (24.7% and 39.7%, respectively) and the
conventional treatment group (26% and 35.4%, respec-
tively). Nor did they differ in the GLUCONTROL trial
performed in 1,078 medical and surgical ICU patients
[19]. The NICE-SUGAR trial in 6,022 ICU patients
reported a higher 90-day mortality rate in the tight glu-
cose control group (4.5 to 6 mmol/L) than in the con-
ventional treatment group (< 10 mmol/L) (27.6 vs
24.9%, P = 0.02) [14]. Glucose control in ICU patients
was found to be beneficial in terms of mortality and
morbidity in the oldest meta-analysis [20] but was with-
out effect in the two most recent meta-analyses, even
after inclusion of the NICE-SUGAR trial results [21-23].
All these studies are difficult to interpret and to com-
pare because of differences in patient populations and
protocol (glucose target levels and measurement meth-
ods, carbohydrate intake), and because of methodologi-
cal weaknesses: single-center studies [4,15,17,18],
surgical and/or medical patient populations [4,15,16],
early study discontinuation [16,19], and difficulty in
reaching the target glucose level [14,16,19]. Currently, it
is not possible to establish a universal glucose threshold
that might provoke toxicity in ICU patients, irrespective
of their disease and environment.
There is no evidence for a benefit of tight glucose
control in an emergency situation. Even if hyperglycemia
on patient admission to hospital is a marker of a poor
prognosis in acute cerebral and cardiovascular disease
[24-27], no study so far has shown a short-term benefit
of tight glucose control in such emergencies [28-32].
The absence of benefit is largely outweighed by a poten-
tially highly harmful increase in the risk of
hypoglycemia.
Several studies have confirmed that acute glucose var-
iations are an independent predictive factor of mortality
[13,33-35]. The greater the variations and the closer the
mean glucose level to normal, the higher the mortality
(the effect is less marked if mean glucose is high >150
mg/dL) [32]. These harmful effects could be related to
endothelial dysfunction and increased oxidative stress,
although not reported in critically ill patients.
No study has assessed different methods of hypergly-
cemia management in ICUs. The need for optimal effi-
cacy (reaching target values and minimizing variations)
and for maximum safety (reducing the incidence of
hypoglycemia) is nevertheless a strong argument in
favor of continuous intravenous insulin infusion by an
electric syringe pump. In ICU patients with edema or
vasomotor variations, intravenous infusion minimized
fluctuations in insulin absorption and enabled delivery
to be adapted fast and effectively to variations in glucose
levels [36,37]. By adjusting insulin delivery rate in
advance, it might be possible to prevent hyperglycemia
induced by glucose intake (food) or drugs (glucocorti-
coids), but no study addressed this question in critically
ill patients. Subcutaneous insulin absorption is unreli-
able and may be unpredictable in patients with edema
or shock; glucose control occurs haphazardly [38]. In a
perioperative study in diabetic patients, target values
were reached in only 40% of patients after subcutaneous
insulin [36].
Hypoglycemia: diagnosis and harms
The definitions of hypoglycemia and its severity are well
established for diabetic patients [39,40]. A third party
has to be present to confirm the degree of severity
before oral or intravenous glucose may be administered.
However, there are no published data or definitions for
hypoglycemia in ICU patients. Unlike in diabetic
patients, it is arbitrarily and exclusively defined on the
basis of a biological threshold without taking any
account of neurologic signs. Most studies conducted in
ICUs were not designed to assess hypoglycaemia and
rely only on the definition based on the blood glucose
concentration, regardless of associated clinical signs
(< 2.2 mmol/L) [3,4,14-18,41].
The definition of severe hypoglycemia used in diabetic
patients cannot be transposed directly to ICU patients
who may be unable to describe clinical signs because of
spontaneous or sedation-induced consciousness disor-
ders. Other cardiovascular clinical signs may also escape
attention. The lack of a specific sign and the inability to
detect early warning signs increase the risk of severe
hypoglycemia [3,19,41]. Most cases of hypoglycemia
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and exclusively biology-based with no report of a clinical
sign of severity [42].
In most studies, hypoglycemia is associated with a sig-
nificant increase in mortality (relative risk: 2.3 to 3.8)
[4,16,19,43,44]. Other studies have, however, suggested
that hyperglycemia is not an independent predictive fac-
tor of mortality [45-47]. Current evidence can therefore
neither refute nor establish a causal relationship. Recent
data have, however, highlighted factors that predispose
to hypoglycaemia such as continuous haemofiltration,
diabetes, mechanical ventilation, sepsis, administration
of insulin and inotropic drugs [45-47], and brain lesions
[48]. In such situations, the effects of a strategy target-
ting a higher glucose target level should be evaluated.
Most ICU studies use at least one episode of severe
hypoglycemia as a yardstick to report hypoglycemia inci-
dence. The incidence (5 to 25% according to study) is
always significantly higher than in the control group.
The most recent studies report a three- to six-fold
increased risk of severe hypoglycemia [20,22,45-55].
The available evidence related to the clinical conse-
quences of long-lasting severe hypoglycemia and its cor-
rection is not reported from critically ill patients. In
experimental models, post-hypoglycemic neuronal death
is not directly due to an energy deficit but arises from a
cascade of reactions triggered by hypoglycemia, in parti-
cular a glutamate and zinc influx that activates post-
synaptic glutamate receptors. This leads to numerous
cellular modifications (for example, production of reac-
tive oxygen species (ROS), DNA modifications and
impairment of membrane permeability) resulting in neu-
ronal apoptosis [49]. Using an experimental model for
severe hypoglycemia, Suh et al. showed that neuronal
death hardly occurred during hypoglycemia but was
marked during glucose reperfusion [50]. Neuronal death
was proportional to the hyperglycemic rebound induced
by exogenous glucose reperfusion, and was induced by
NADPH oxidase, responsible for ROS production. This
is reminiscent of the mechanisms of cellular death dur-
ing episodes of reperfusion following ischemia. Despite
the lack of clinical evidence supporting these experi-
mental data, and because of variability in glucose levels,
more rigorous management of hypoglycemia (infusion
of a more moderate amount of glucose and closer moni-
toring) could be needed to prevent an excessive hyper-
glycemic rebound.
The higher incidence of hypoglycemia during tight
glucose control, associated with the frequent absence of
clinical warning signs, calls for repeated glucose mea-
surements. However, there is no study that can be used
as a basis to recommend any given interval between
measurements as a function of the equilibrium observed:
from 30 minutes (in cases of hypoglycemia or severe
hyperglycemia) to 4 hours depending upon glucose level
stability and study [4,15-19].
Irrespective of measurement method, glucose levels
vary according to sampling site, as recently confirmed in
patients with shock or edema [51-55]. Values measured
on capillary samples are overestimated compared to
those measured on arterial samples [53,54]. The discre-
pancy would be 30% according to the most recent data
[14,53]. However, approximate measurements for non
severe hypoglycemia are not acceptable in patients with
no clinical signs of severity. A control measurement
should be performed on arterial or venous blood in the
laboratory or using a blood gas/glucose analyzer. This
approach, widely used in diabetics [40], was applied in
the recent NICE-SUGAR trial [14]. There have been
reports of episodes of severe hypoglycemia that have
remained undetected by point-of-care capillary blood
analyzers [56].
Carbohydrate intake
Hyperglycemia probably has beneficial or harmful effects
depending upon the mechanism of its onset, its severity,
and duration [41]. Stress diabetes is a transitory
abnormality induced by acute disease (inflammation,
ischemia-reperfusion) and a marker of disease severity.
It is also an adaptive response for overcoming the acute
metabolic changes observed in ICU patients [3,57-59].
Faster glucose turnover and insulin resistance initially
provide the amount of energy substrate (glucose) that
some organs need [57,60,61]. Hypoxia and proinflamma-
tory phenomena (cytokines) intensify this endogenous
hyperglycemia, and vice-versa, thus creating a vicious
circle. The hyperglycemia can be worsened and pro-
longed by the development of exogenous hyperglycemia
through enteral or parenteral glucose intake or gluco-
corticoid administration. The glucose that was initially
useful is now present in excess and becomes toxic by
enhancing inflammatory responses and inducing oxida-
tive stress [62-64]. The different outcomes in the Leuven
and NICE-SUGAR trials might be partly due to differ-
ences in carbohydrate intake levels. Van den Berghe
et al. administered high carbohydrate levels (200 g/day)
[4]. This could have enhanced glucose toxicity. The glu-
cotoxicity would have been reversed by intensive insulin
therapy. In contrast, enteral carbohydrate administration
in the NICE-SUGAR trial was restricted especially dur-
ing the first two to three days [14]. Early insulin admin-
istration to induce a return to normal glucose values
might have worsened the patients’ conditions by pre-
venting an adaptive response.
There is no evidence justifying either the continua-
tion or interruption of intravenous insulin therapy
once ICU patients have resumed food intake. The
duration of glucose monitoring in ICUs has not been
Ichai et al. Critical Care 2010, 14:R166
http://ccforum.com/content/14/5/R166
Page 5 of 11investigated in a well-designed study (except in dia-
betic patients). According to physiopathological data, it
is reasonable to expect that patients who can eat have
recovered glucose regulation with appropriate endo-
genous insulin secretion, in particular before meals. All
RCTs have used the following regimen: intravenous or
subcutaneous preprandial insulin bolus with at least
one glucose measurement before each meal [4,14,19].
Glucose monitoring was stopped once the patient left
the ICU. Some studies have recommended substituting
subcutaneous for intravenous insulin before the patient
leaves the ICU [65]. A retrospective study in neurosur-
gery patients has shown that 6 to 70% of the intrave-
nous insulin dose, administered by the subcutaneous
route, provided satisfactory glucose control with no
increase in risk of hypoglycemia [66].
The recommended daily energy intake in ICU patients
is about 25 kcal/kg/day [67]. It may take at least two to
three days to reach this objective. If the enteral calorie
intake is still too low after three days, parenteral supple-
mentation may be used [67]. Glucose is a key energy
substrate; some tissues depend totally or highly on glu-
cose. Mean daily consumption by the brain is 100 to
1 5 0g .T h es o u r c em a yb ee x o g e n o u so re n d o g e n o u s .
Exogenous glucose comes from enteral or parenteral
carbohydrate intake. Endogenous glucose comes mostly
from hepatic or muscular neoglucogenesis and can
reach 300 g/day [68]. ICU patients are insulin resistant
and too much exogenous glucose increases the risk of
hyperglycemia [1], in particular as maximum glucose
oxidation capacity is reduced to 2 to 5 mg/kg/minute
[57,69,70]. In such a situation, glucose infusion only par-
tially inhibits neoglucogenesis. However, these observa-
tions apply to short periods (less than three days) in
cohorts of critically ill ICU patients [71], and assessment
of the impact of enteral carbohydrates on glucose meta-
bolism remains difficult (the estimated true digestive
absorption is not very reliable). On the other hand, no,
or very little, exogenous glucose may hasten neogluco-
genesis substrate use and muscle protein catabolism. In
summary, total glucose deprivation (fasting) or a too
high intake clearly have harmful effects in ICU patients.
However, optimal carbohydrate intake has still to be
established [67].
The impact of carbohydrate intake on glucose levels in
ICU patients suggests that glucose control protocols
should take account of carbohydrate intake [72]. In the-
ory, this should achieve optimal glucose control by fore-
seeing variations in glucose levels (hyper- and
hypoglycemia). According to several reports, the perfor-
mance of glucose control software accounting for carbo-
hydrate intake is satisfactory [73-77]. However, its
benefits have yet to be demonstrated in routine clinical
practice.
Glucose monitoring
The gold standard measurement is one made in the
laboratory on an arterial or venous blood sample using
hexokinase [78,79]. Point-of-care glucometers use other
enzymes (glucose oxidase (GO) or glucose dehydrogen-
ase (GDH)). GO is the enzyme used in the older models.
It is less stable than GDH and therefore less precise, and
has more limitations. Point-of-care glucose readers must
comply with strict standards (ISO 15197 in Europe)
regardless of the enzyme used, that is, a deviation with
respect to the gold standard of <15 mg/dL for glucose
levels above 75 mg/dL and a maximum 20% deviation
for higher levels [80]. Most devices meet these standards
but none yields a more accurate measurement (< 10%
deviation) [52,53].
The sampling site may influence glucose measure-
ments and be a source of discordant values. Gluc-
ometers may well comply with international standards,
but they were devised to measure glucose in capillary
blood from ambulatory patients. The reliability of their
use in ICU patients is a matter of controversy
[51,52,54,55,80]. The main sources of discrepancies are
vasoconstriction, low blood flow rate, a state of shock,
ischemia, or edema [54,78,79]. In such cases, about 15%
of capillary measurements vary by >20% with respect to
the gold standard [78,81]. The discrepancies are worse
in cases of hypoglycemia, thus justifying confirmation in
the laboratory [54]. Measurements on arterial blood
show the least variation.
As plasma is richer in water than red blood cells, glu-
cose measurements on plasma are higher than on total
blood, by about 10 to 15% [79]. The discrepancy is even
greater in cases of abnormal hematocrit values. The
World Health Organisation (WHO) recommends that
plasma values be converted into laboratory total blood
values by applying a correction factor of 1.12. However,
plasma glucose does not depend on the hematocrit
value and reflects active glucose more faithfully. For this
reason, and in order to avoid any errors in interpreta-
tion, the American Diabetes Association and the Inter-
national Federation of Clinical Chemistry and
Laboratory Medicine Scientific Division (IFCC) have
urged that practice be harmonized by considering
plasma glucose only, regardless of sampling site and
m e a s u r i n gd e v i c e[ 7 9 ] .T h e yr e c o m m e n dac o r r e c t i o n
factor of 1.1 to be applied to results for total blood.
Most recent devices using paper-strip blood sampling
have in-built automatic correction and provide plasma
values [80,82].
Point-of-care glucose meters use different measure-
ment methods (amperometric or colorimetric reaction,
enzymatic reaction (GO or GDH), calibration on total
blood or plasma, and different blood volumes) which
all lead to device-specific limitations, interferences, and
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are influenced by blood oxygen concentration as oxy-
gen is involved in catalysis. GDH devices use either
PQQ (pyrroloquinolone quinone) or FAD (flavine ade-
nine dinucleotide) for catalysis. Depending upon the
device, certain physicochemical factors can impair
measurement accuracy. Sampling conditions and inter-
pretation of results must therefore take the type of
device into account [78]. The PaO2 value, very high or
low pH values, hypothermia, and altitude can influence
measurements made with GO devices [87,88]. With
the oldest GO devices (amperometric reaction), PaO2
values of <40 mmHg may overestimate glucose by
about 15%. The more recent GO devices (colorimetric
r e a c t i o n )a r em o r er e l i a b l eo v e raw i d eP a O 2 range
[87]. GDH devices are not affected by the PaO2 value,
but high galactose or maltose concentrations may
overestimate values given by GDH PQQ devices. Cases
of wrong results resulting in the death of the patient
have led to banning their use in such situations
[89,90]. All GDH devices (PQQ or FAD) overestimate
values in the presence of high concentrations of some
substances (endogenous substances: uric acid, bilirubin,
triglycerides; exogenous substances: xylose, salicylate,
paracetamol, mannitol). This information is supplied in
the manufacturer’s instructions [78]. Many continuous
glucose monitoring systems (subcutaneous or intravas-
cular measurements) are being developed and assessed.
Their reliability in ICUs has yet to be demonstrated
[3]. In summary, the reliability of the results depends
on the user’s knowledge of the device.
Algorithms and protocols
The early results of Van den Berghe et al. led to the
widespread use of continuous insulin therapy for glucose
control. Hospital teams drafted protocols to promote
efficacy and safety. A wide variety of algorithms have
been published because the choice of criteria is vast: tar-
get glucose, insulin delivery rate, monitoring interval,
management by doctors or nurses, and so on. In Van
den Berghe et al.’s trial, the algorithm was implemented
by a specially trained nursing staff [4]. On the other
hand, in the NICE-SUGAR trial, a web-based compu-
terised protocol with several entries was used to provide
insulin delivery rates and monitoring intervals [14]. In
all cases, a written protocol suited to local conditions
(technical and human resources) and accepted by the
care team should be implemented in order to guarantee
efficacy and safety [91-93].
No prospective RCT has compared the impact of glu-
cose control protocols on morbidity and mortality. It is
difficult to assess algorithm performance because of the
variety of variables used. Currently, there is no evidence
for choosing one protocol rather than another.
Continuous intravenous insulin provides greater effi-
cacy, safety, and ease of use than subcutaneous adminis-
tration in ICUs [3,41,91,94,95]. It is used by virtually all
ICUs and is sometimes supplemented by intravenous
boli. It has the advantage of limiting wide variations in
glucose; this is as important as the mean hyperglycemia
value [13,12,34,41]. In addition, although a causal rela-
tionship between hypoglycemia and increased mortality
has not been proven, it is prudent to recommend glu-
cose control techniques that limit these episodes as far
as possible [65].
A study of 100 ICU patients has shown that the inci-
dence of severe hypoglycemia was significantly reduced
when insulin was administered by a specific rather than
non specific infusion route (4% vs 22%) [96]. As for con-
tinuous catecholamine administration, this helps avoid
any variations in delivery that may be induced by the
injection of other drugs.
Static control algorithms determine insulin delivery
rate from a single (the last) glucose measurement.
Dynamic control algorithms take a wide variety of other
factors into account such as the ongoing insulin delivery
rate, monitoring interval, glucose intake, and so on. This
accounts for protocol diversity. Available evidence
shows that dynamic control is better than static control
[91]. The approach used should also take account of
exogenous glucose intake which may affect glucose
levels [72-77]. Ideally, intake should be anticipated in
order to achieve more stable glucose levels [3].
Entry variables are those that spark off recommenda-
tions whereas output variables are those that make up
the recommendations. The entry invariably used is glu-
cose value but other entries such as previous insulin
delivery rate and the monitoring interval may be taken
into account. The output common to all algorithms is
the insulin delivery rate. Other possible outputs are
recommendations concerning insulin boli, food intake,
monitoring interval, hypoglycemia correction, and so on.
The number of entries and outputs make non compu-
ter-assisted protocol management well-nigh impossible.
The complexity of the paperwork of the NICE-SUGAR
trial might explain the limited time spent in-target
(40%), the low proportion of eligible patients (15%), and
the short monitoring intervals increasing workload [14].
Dedicated computer software is being developed
[76,77,97-99]. There are two types of computer-assisted
second generation software using complex algorithms:
(i) Proportional-Integral-Derivative (PID) software uses a
closed-loop control that takes into account the devia-
tions with respect to target glucose value, time in-target,
and variations in level [77,100]. The changes in insulin
delivery rate are always based on past measurements; (ii)
Model Predictive Control (MPC) software predicts glu-
cose values using established models [74,76,98].
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consider attainment of the target glucose value but also
protocol adoption time by staff, risk of hypoglycemia,
and the variability and reliability of measurements
[73-77,91].
The efficacy of glucose control depends on factors
that differ considerably among studies. Recent work has
tried to establish the factors needed to validate protocol
efficacy [101-103]. The most important seem to be
hyperglycemia index and variability. The frequency and
severity of hypoglycemia reflect protocol safety.
The introduction of glucose control in ICUs increases
staff workload because of protocol implementation time
and repeated monitoring. In a prospective single-center
study, the time required was two hours per day, that is,
about 20% of a nurse’s working day [104]. For a proto-
col to be effective and safe, its feasibility should be tai-
lored to resources; close cooperation is needed between
doctors and nurses for the procedure to take account of
local technical and human resources. Users must accept
the protocol and training [105]. Despite these measures,
failure in reaching the target glucose value has been
reported in over 30% of patients [106].
Conclusions
Glucose control in ICUs should be a therapeutic objec-
tive. It is no longer possible to overlook severe hypergly-
cemia (> 10 mmol/L) although it is not yet possible to
recommend a single glucose threshold common to all
types of patients and diseases, especially as glucose con-
trol exposes patients to an increased risk of potentially
harmful hypoglycemia. In addition, although mean glu-
cose is an important therapeutic target to be achieved,
recent data underscore the impact of many other factors
(for example, variability in glucose levels, carbohydrate
intake, presence or not of chronic hyperglycemia (dia-
betes). The safety and reliability of glucose monitoring
techniques also need to be taken into account. Progress
in the accuracy, harmonisation, and automation of these
techniques is needed to enhance the efficacy and safety
of glucose control, and diminish workload. There is no
question of introducing tight glucose control into ICUs
at all costs. However, further studies are needed to
answer many unsolved questions: Which target glucose
values should be used in which patients? How to moni-
tor glucose levels? Which protocols should be used? In
the meantime, each team should set up formal protocols
in line with their technical and human resources.
Key messages
￿ Stress-induced hyperglycemia has been found to be
associated with an increased morbi-mortality in critically
ill patients. Thus, an excessive hyperglycemia (> 10
mmol/L) should be avoided in adult ICU patients.
￿ Due to persistent conflicting data and the increased
risk of hypoglycemia, strict glycemic control cannot be a
universal strategy regardless of the condition of patient
and the training of the team.
￿ Continuous intravenous insulin is the only strategy
permitted to efficiently control glycemia while decreas-
ing the risk of glycemic variations in critically ill
patients.
￿ In ICU, severe hypoglycemia (< 2.2 mmol/L) should
be detected, even in the absence of warning clinical
signs, using a close glycemic monitoring (repeated blood
samples).
￿ Blood glucose concentrations determined with bed-
side point-of-care glucometers provides inaccurate mea-
surements in critically ill patients. Thus, blood glucose
measures should be preferentially performed on arterial
(or venous) blood samples using classical laboratory
devices or blood gas/glucose analyzers, especially in the
case of extreme values.
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